R & D Strategy
Compared to large biomolecules, small molecules (MW < 1,500) typically have stronger abilities to penetrate biological barriers, more accessible targets, and can simultaneously act on multiple proteins. Small molecule drugs provide a cost-effective treatment option for global patients due to their more convenient methods of administration, higher stability and convenience in storage and transportation, as well as lower production and drug costs.
However, due to the smaller contact area with target proteins and fewer interatomic interactions, small molecules require more creative structural design to achieve the desired biological specificity and drug-like properties. Tyligand Bioscience aims to create highly selective small molecule ligands with multiple and precise regulation of signal protein phosphorylation levels, relying on the team's in-depth understanding of biological targets and rich experience in synthetic chemistry, providing more effective, safer, more convenient, and more economical solutions for patients to restore health.

Cancers
Focus on carcinogenesis and tumor tissue characteristics
The phenotypic heterogeneity and evolutionary capacity of malignancies pose great challenges to the task of curing advanced cancers with drugs targeting a single signaling pathway. First, tumor cells have basically the same genome and functions as normal cells, and use normal growth and anti-apoptosis mechanisms to proliferate indefinitely, making it difficult for the immune system to recognize them. The mechanistic dependence of the human immune system on homeostasis and the complexity of multiple regulation provide opportunities for tumor escape.
At the same time, the organized tumor cells create a microenvironment suitable for growth, providing nutrient flow, waste disposal, information transmission and other services and structural support, as well as border defenses that hinder immune cell intervention and drug penetration. Therefore, the drug resistance of targeted therapy and the universality of immunotherapy have become the main challenges of cancer research in the world today.
We focus on the carcinogenesis mechanism and tumor tissue characteristics at the molecular level, and are committed to discovering drugs that can precisely and multi-pathway regulate the conduction of oncogenes and their expressed protein signals, providing patients with effective, safe, convenient and accessible treatment options.
Autoimmune Diseases

Due to differences in individual genetic factors and growth environments, the factors leading to the pathogenesis of autoimmune diseases, that is, the imbalance of immune cell functions, are very complicated, but they are mainly related to the appearance of self-antigens. If the immune system resists foreign invading pathogens, such as bacteria, if the antigenic components targeted are the same or similar to the antigenic components of the human body's own cells, the resulting antibodies will also produce an immune response to the own tissues. In addition, certain body components hidden in the body that are normally insulated from the immune system can also become antigens that trigger autoimmune responses when released due to trauma or other reasons.
Traditional treatments rely on drugs that reduce the activity of the immune system, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDS), and antipurine metabolizers such as methotrexate. A new generation of macromolecular biological drugs selectively blocks the signal transmission of pro-inflammatory factors and their receptors in the body. The side effects and scope of application of these drugs limit their application and effect. We work closely with medical professionals to discover unmet patient needs and actively develop new drugs that act on novel mechanisms and are highly selective for the treatment of autoimmunity.